Late 2013, Elizabeth started treatment for multidrug-resistant tuberculosis (MDR-TB) at MSF’s Green House Clinic in Nairobi.
Five months later, treatment was not having any effect and she was diagnosed with a more severe form of the disease, extensively drug-resistant tuberculosis (XDR-TB).
Elizabeth’s new treatment included Bedaquiline. She was the first patient in Kenya to receive this new anti-TB drug. Her treatment lasted 24 months.